Consano Bio, today announced that management will participate in two upcoming industry conferences to highlight C-1101, the company’s novel, platelet-derived multi-protein biologic therapeutic designed to treat lumbosacral radiculopathy (LSR), or chronic sciatica. ...
Consano Bio, today announced that it has completed an oversubscribed financing, raising more than its $15 million target to support the clinical development of C-1101, the company’s lead investigational therapy. The financing was subscribed by a syndicate of accredited private investors, and including this transaction,...
Consano Bio, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to C-1101, the Company's lead investigational, platelet-derived biologic for the treatment of chronic, painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. Presently, there are no FDA-approved pharmaceutical...
Consano Bio, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to C-1101, the Company's lead investigational, platelet-derived biologic for the treatment of chronic, painful lumbosacral radiculopathy (LSR), commonly known as chronic sciatica. Presently, there are no FDA-approved pharmaceutical...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101, the company’s potential first-in-class, disease-modifying, non-opioid therapy...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today highlighted the role of its Scientific Advisory Board (SAB) in guiding the company’s scientific and clinical strategy as it advances C-1101, the company’s potential first-in-class, disease-modifying, non-opioid therapy...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that Andrew Hall, Chief Executive Officer will present at BIO International Convention, being held June 22-25, 2026, in San Diego, California....
Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious painful orthopedic conditions, today announced that the first patient has been successfully dosed in its first Phase 1 clinical trial (C-1101-101, NCT07264270) evaluating C-1101 in patients with chronic, painful lumbosacral radiculopathy...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced the presentation of preclinical data supporting its lead investigational therapy, C-1101, at the Orthopaedic Research Society (ORS) 2026 Annual Meeting in Charlotte, NC. The data were presented in...
Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that CEO Andrew Hall will present at the BIO Investment & Growth Summit, taking place March 2–3, 2026, in Miami, Florida....